Download Library
Document Type
Two Phase 3 studies of the efficacy and safety of AR13324 Ophthalmic Solution 0.02%: in Patients with Open Angle Glaucoma and Ocular Hypertension
Presentations
Visualization of tissue response to netarsudil in living mouse eyes
Presentations
Anti-fibrotic Effects of AR-13324 in a 3D Bioengineered Human Trabecular Meshwork Model
Presentations
Topical Administration of a ROCK/NET Inhibitor Promotes Retinal Ganglion Cell Survival and Axon Regeneration
Presentations
The Mechanisms of Increasing Outflow Facility by AR-13324M in Human Eyes
Presentations
AR-13324 Ophthalmic Solution 0.02%: Topline Results of Two Phase 3 Clinical Studies in Patients with Open Angle Glaucoma and Ocular Hypertension
Presentations
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Presentations
Aerie Pharmaceuticals Investor & Media Briefing
View Presentation
View Presentation
Page: FirstPrevious
2
NextLast
= add file to Briefcase